# A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

> **NCT05206604** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-07295324
- **DRUG:** PF-07259955

## Key facts

- **NCT ID:** NCT05206604
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-09
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206604, "A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05206604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*